Phosphorylated NPY1R Modulates VSMC Phenotype and Inflammation in Intracranial Aneurysm Progression

Study Background and Research Question

Intracranial aneurysm (IA) is a localized dilation of cerebral arteries that can rupture and cause subarachnoid hemorrhage, leading to high rates of morbidity and mortality. While surgical and endovascular interventions are available, their risk profiles stimulate ongoing search for molecular mechanisms underlying IA formation and rupture. Accumulating evidence implicates both vascular smooth muscle cell (VSMC) phenotypic plasticity and immune cell infiltration as central to aneurysm progression. However, the upstream regulators of these processes remain incompletely defined. The reference study (He et al., Neuropeptides, 2024) investigates whether the neuropeptide Y1 receptor (NPY1R), particularly in its phosphorylated state, orchestrates VSMC phenotypic transition and inflammatory responses to drive IA progression.

Key Innovation from the Reference Study

The central innovation of this research is the identification of phosphorylated NPY1R as a regulatory node linking VSMC contractile-to-synthetic phenotype transition and macrophage-driven inflammation within aneurysm tissue. By demonstrating that tyrosine kinase (TK)-mediated phosphorylation of NPY1R is required for its pathogenic effects, the study opens a new mechanistic axis in vascular remodeling distinct from canonical GPCR pathways. The authors further show that pharmacological inhibition of TK activity or depletion of macrophages can reverse the deleterious consequences of NPY1R overexpression, positioning these pathways as actionable targets for future IA therapies.

Methods and Experimental Design Insights

To address the hypothesis, the investigators employed a multi-tiered approach:

• Clinical and animal tissue analysis: Human IA samples and a mouse IA model (induced by systemic hypertension and elastase injection) were used to quantify NPY1R expression and correlate it with inflammatory cell infiltration.
• Cellular assays: VSMC phenotype was monitored via expression of contractile (e.g., α-SMA) and synthetic (e.g., osteopontin) markers, using RT-qPCR and western blotting.
• Inflammatory profiling: Flow cytometry and immunofluorescence quantified T cells, macrophages, and neutrophils; ELISA measured cytokine levels.
• Mechanistic interrogation: Co-immunoprecipitation established the physical interaction and phosphorylation status of NPY1R by TK.
• Intervention studies: Tyrosine kinase inhibitors (TKI) and macrophage ablation (using clodronate liposomes) tested the functional relevance of these pathways in IA progression.

This integration of in vivo, ex vivo, and molecular analyses allowed the authors to dissect causality and downstream consequences of NPY1R signaling in the context of aneurysm biology.

Core Findings and Why They Matter

• NPY1R is significantly upregulated in both human and mouse IA tissues, with expression levels positively correlating to macrophage infiltration (He et al., 2024).
• Overexpression of NPY1R in mice promotes a shift in VSMCs from a contractile to a synthetic phenotype, characterized by downregulation of contractility proteins and enhanced migratory capacity—hallmarks of vascular remodeling and IA vulnerability.
• NPY1R overexpression also increases local inflammatory responses, especially the polarization of macrophages toward the pro-inflammatory M1 phenotype.
• Tyrosine kinase–mediated phosphorylation of NPY1R is required for these effects. Inhibiting TK activity reduces NPY1R phosphorylation, suppresses VSMC phenotypic switching, dampens inflammatory signaling, and ultimately decreases IA formation and rupture risk.
• Macrophage depletion in mice reverses the IA-promoting effects of NPY1R overexpression, underscoring the interdependence of VSMC phenotype and inflammatory cell recruitment in aneurysm progression.

Together, these findings suggest a feed-forward loop in which phosphorylated NPY1R orchestrates both the structural remodeling of the vascular wall and the immune microenvironment that underlies IA pathogenesis. This advances our understanding of how neuropeptide receptor signaling integrates with vascular and immune cell biology in complex vascular diseases.

Comparison with Existing Internal Articles

While the reference study uniquely highlights NPY1R phosphorylation as a driver of VSMC phenotypic modulation and inflammation, related literature on Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) provides complementary perspectives on vascular remodeling. For example, the article "Angiotensin II in Vascular Smooth Muscle Cell Hypertrophy" outlines how Angiotensin II, through G protein-coupled receptor (GPCR) activation, induces VSMC hypertrophy and contributes to hypertension and aneurysm models. Similarly, "Angiotensin II in Vascular Hypertrophy and Hypertension Models" details protocols leveraging Angiotensin II to model cardiovascular remodeling, paralleling the mechanisms observed for NPY1R in the reference study.

Notably, both Angiotensin II and NPY1R signaling converge on VSMC plasticity, inflammatory signaling, and vascular wall remodeling. However, the reference investigation provides new insight by connecting these processes to neuropeptide receptor phosphorylation and its downstream consequences—an axis not directly addressed in Angiotensin II–focused protocols but highly relevant for next-generation vascular disease models.

Limitations and Transferability

Despite its mechanistic depth, the study’s primary limitations include reliance on murine models, which may not fully recapitulate human IA pathophysiology, and the focus on a single neuropeptide receptor pathway. The interaction between NPY1R and other vasoactive mediators—such as Angiotensin II—remains an open question. Moreover, therapeutic translation of tyrosine kinase inhibition or macrophage depletion strategies requires further validation for safety and efficacy in clinical settings. This underscores the need for integrated studies leveraging multiple pathway modulators and humanized models to enhance transferability.

Protocol Parameters

• VSMC phenotype modulation: Overexpression or knockdown of NPY1R in VSMCs to assess contractile versus synthetic marker expression.
• Inflammatory profiling: Flow cytometry and ELISA to monitor immune cell populations and cytokine levels in aneurysm tissues.
• Pharmacological interventions: Tyrosine kinase inhibitors administered during IA induction to interrogate the requirement for NPY1R phosphorylation.
• Macrophage ablation: Use of clodronate liposomes to selectively deplete macrophages in vivo and evaluate effects on IA progression.
• Reference for Angiotensin II–based protocols: Typical administration of 100 nM Angiotensin II for 4 hours in cell culture or 500–1000 ng/min/kg in murine models to induce vascular remodeling, as detailed in relevant internal workflows.

Research Support Resources

Researchers aiming to model vascular remodeling, VSMC phenotypic transitions, or vascular inflammation can employ established agents such as Angiotensin II (SKU A1042) to recapitulate key features observed in IA and related pathologies. This research-grade peptide, as described in the product dossier, enables reproducible induction of VSMC hypertrophy, hypertension, and vascular inflammatory responses in both in vitro and in vivo settings. For optimal results, follow recommended protocols for preparation, dosing, and storage. For further methodological guidance, see internal articles detailing Angiotensin II–based cardiovascular remodeling workflows and troubleshooting strategies. APExBIO provides validated Angiotensin II for research use in these advanced vascular models.